Prevention of Infection in Adults Receiving Intravenous Antibiotic Treatment via Indwelling Central Venous Access Devices

Author(s): Basant K. Puri*, Anne Derham, Jean A. Monro

Journal Name: Reviews on Recent Clinical Trials

Volume 14 , Issue 1 , 2019

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: The use of indwelling Central Venous Access Devices (CVADs) is associated with the development of bloodstream infections. When CVADs are used to administer systemic antibiotics, particularly second- or higher-generation cephalosporins, there is a particular risk of developing Clostridium difficile infection. The overall bloodstream infection rate is estimated to be around 1.74 per 1000 Central Venous Catheter (CVC)-days.

Objective: We hypothesised that daily oral administration of the anion-binding resin colestyramine (cholestyramine) would help prevent infections in those receiving intravenous antibiotic treatment via CVADs.

Method: A small case series is described of adult patients who received regular intravenous antibiotic treatment (ceftriaxone, daptomycin or vancomycin) for up to 40 weeks via indwelling CVADs; this represented a total of 357 CVC-days. In addition to following well-established strategies to prevent C. difficile infection, during the course of the intravenous antibiotic treatment the patients also received daily oral supplementation with 4 g colestyramine.

Results: There were no untoward infectious events. In particular, none of the patients developed any symptoms or signs of C. difficile infection, whereas approximately one case of a bloodstream infection would have been expected.

Conclusion: It is suggested that oral colestyramine supplementation may help prevent such infection through its ability to bind C. difficile toxin A (TcdA) and C. difficile toxin B (TcdB); these toxins are able to gain entry into host cells through receptor-mediated endocytosis, while anti-toxin antibody responses to TcdA and TcdB have been shown to induce protection against C. difficile infection sequelae.

Keywords: Ceftriaxone, central venous access device, Clostridium difficile infection, colestyramine, daptomycin, vancomycin.

Buxton ILO. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th ed. Brunton, LL, Hilal-Dandan, R, Knollmann, BC, Eds.; McGraw Hill: New York, 2018, pp. 13-54
Ho C, Spry C. In: Central Venous Access Devices (CVADs) and Peripherally Inserted Central Catheters (PICCs) for Adult and Pediatric Patients: A Review of Clinical Effectiveness and Safety: Ottawa (ON), 2017
Zhang Z, Brusasco C, Anile A, et al. Clinical practice guidelines for the management of central venous catheter for critically ill patients. J Emerg Crit Care Med 2018; 2.
Vardakas KZ, Polyzos KA, Patouni K, et al. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 2012; 40: 1-8.
Napolitano LM, Edmiston CE Jr. Clostridium difficile disease: Diagnosis, pathogenesis, and treatment update. Surgery 2017; 162: 325-48.
McAdam AJ, Milner DA, Sharpe AH In:. Robbins and Cotran Pathologic Basis of Disease Kumar, V, Abbas, AK, Aster, JC, Eds Elsevier Saunders: Philadelphia, PA, 2015; pp. 341-402.
Turner JR In:. Robbins and Cotran Pathologic Basis of Disease Kumar, V, Abbas, AK, Aster, JC, Eds; Elsevier Saunders: Philadelphia, PA, 2015; pp. 749-819.
Lipitz-Snyderman A, Sepkowitz KA, Elkin EB, et al. Long-term central venous catheter use and risk of infection in older adults with cancer. J Clin Oncol 2014; 32: 2351-6.
Brandt CF, Tribler S, Hvistendahl M, et al. Home Parenteral Nutrition in Adult Patients With Chronic Intestinal Failure: Catheter-Related Complications Over 4 Decades at the Main Danish Tertiary Referral Center. JPEN J Parenter Enteral Nutr 2016; pii: 0148607116678766.
Santarpia L, Buonomo A, Pagano MC, et al. Central venous catheter related bloodstream infections in adult patients on home parenteral nutrition: Prevalence, predictive factors, therapeutic outcome. Clin Nutr 2016; 35: 1394-8.
Puri BK, Hakkarainen-Smith JS, Monro JA. The potential use of cholestyramine to reduce the risk of developing Clostridium difficile-associated diarrhoea in patients receiving long-term intravenous ceftriaxone. Med Hypotheses 2015; 84: 78-80.
Psichas A, Little T, Lal S, McLaughlin J. Colestyramine slows gastric emptying of liquids and reduces appetite in healthy subjects. Neurogastroenterol Motil 2012; 24: 1095-101.
Olling A, Hüls C, Goy S, et al. The combined repetitive oligopeptides of clostridium difficile Toxin A counteract premature cleavage of the glucosyl-transferase domain by stabilizing protein conformation. Toxins 2014; 6: 2162.
Baliban SM, Michael A, Shammassian B, et al. An optimized, synthetic DNA vaccine encoding the Toxin A and Toxin B receptor binding domains of clostridium difficile induces protective Antibody Responses In Vivo. Infect Immun 2014; 82: 4080-91.
Committee JF. British National Formulary. 75 ed. London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society 2018.
Birch T, Golan Y, Rizzardini G, et al. Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection. J Antimicrob Chemother 2018.
Crowell KT, Julian KG, Katzman M, et al. Compliance with Clostridium difficile treatment guidelines: Effect on patient outcomes. Epidemiol Infect 2017; 145: 2185-92.
Borgia G, Maraolo AE, Foggia M, Buonomo AR, Gentile I. Fecal microbiota transplantation for Clostridium difficile infection: Back to the future. Expert Opin Biol Ther 2015; 15: 1001-14.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Published on: 30 January, 2019
Page: [47 - 49]
Pages: 3
DOI: 10.2174/1574887113666180817125036
Price: $65

Article Metrics

PDF: 34